Caption Management’s ACELYRIN SLRN Stock Holding History

Caption Management’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-50,377	Closed	-$512K	–	1643
2023 Q3	$512K	Buy	+50,377	New	+$1.07M	0.01%	933

Other funds holding SLRN

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Caption Management's SLRN Position: Q4 2023 in Review

Caption Management sold out of ACELYRIN (SLRN) in Q4 2023, closing a stake of 50,377 shares — an estimated $512K sold.

Caption Management first reported a position in SLRN in Q3 2023 and held it in 1 quarter. The position peaked at $512K in Q3 2023. 110 funds tracked by Wall St. Rank hold SLRN as of Q4 2023.

Caption Management reported no remaining ACELYRIN position as of Q4 2023 after selling out during the quarter.
Caption Management sold 50,377 ACELYRIN shares in Q4 2023, an estimated $512K.
Caption Management first reported a position in ACELYRIN in Q3 2023 and held it in 1 quarter.
Caption Management's ACELYRIN position peaked at $512K in Q3 2023.
110 funds tracked by Wall St. Rank held ACELYRIN as of Q4 2023.

Based on Caption Management's 13F filing for Q4 2023, filed 14 Feb 2024.